Scienture Q2 Revenue Jumps 510% Sequentially to $344K, Loss Narrows 58%
SCNX has more than doubled off its 52-week low of $0.238.
Summary
Scienture reported Q2 2026 revenue of $343,639, a 510% sequential jump from Q1's $56,325, driven by the commercial launch of REZENOPY. Gross margin was near 98%. Operating loss narrowed 48% year-over-year to $2.7M and net loss narrowed 58% to $2.8M. Cash stood at $11.2M, up from $6.7M at year-end. The company also secured additional patents for REZENOPY and Arbli, extending exclusivity to 2041. This follows the $11M financing facility disclosed in the 10-Q filed yesterday.
At the time of this announcement, SCNX was trading at $0.53 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $18.9M. The 52-week trading range was $0.24 to $2.60. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: GlobeNewswire.